Raoul S. Concepcion, MD, FACS, Urology Associates P.C., Nashville, Tennessee, discusses what combinations of immunotherapy for prostate cancer treatment are most promising.
Interview produced by Prostatepedia
Keywords: combination immuonotherapy, enzalutamide, abiraterone, Provenge, Radium 223, prostate cancer
Raoul S. Concepcion, MD, FACS, discusses managing prostate cancer with a combination of immunotherapeutic agents and other treatment options. Sipuleucel-T (PROVENGE), the only FDA approved immunotherapy for metastatic castration-resistant prostate cancer (mCRPC), does not attack androgen receptors. Therefore, Dr. Concepcion explores the possibility combining sipuleucel-T with androgen excess inhibitors, like abiraterone or enzalutamide, or a sipuleucel-T/radium-223 combination.